|
J Biol Chem, Vol. 273, Issue 17, 10147-10152, April 24, 1998
Prothymosin Stimulates Ca2+-dependent
Phosphorylation of Elongation Factor 2 in Cellular Extracts*
Felix V.
Vega ,
Anxo
Vidal §,
Ulf
Hellman¶,
Christer
Wernstedt¶, and
Fernando
Domínguez§
From the Departamento de Fisiología, Facultad de
Veterinaria, Lugo and § Laboratorios de Neurociencia
"Ramón Domínguez," Departamento de
Fisiología, Facultad de Medicina and Unidad Medicina Molecular,
INGO, 15705 Santiago de Compostela, Spain and ¶ Ludwig
Institute for Cancer Research, 75124 Uppsala, Sweden
 |
ABSTRACT |
Prothymosin (PTA) stimulates in a
dose-dependent manner the phosphorylation of a 105-kDa
protein (p105) in cell extracts from different cell types. Protein
sequencing and immunological analysis indicated that this protein is
elongation factor 2 (EF-2). We propose that
calcium/calmodulin-dependent protein kinase III is
responsible for the PTA-dependent EF-2 phosphorylation
based on the following lines of evidence: (a)
Ca2+ is required for the effect; (b) calmodulin
enhances the reaction, and calmodulin inhibitors block the
phosphorylation; and (c) no phosphorylation is seen in cell
extracts depleted of calmodulin-binding proteins. To obtain a strong
phosphorylated EF-2 band, we found it necessary to add PTA to cytosolic
extracts from synchronized dividing cells in various phases of the cell
cycle except in mitosis. Since PTA is a nuclear protein everywhere in
the cell cycle except in mitosis, when it is found in the cytoplasm, we
hypothesize that, if PTA activates EF-2 phosphorylation in
vivo, as present data suggest, its presence in the cytoplasm
during mitosis could explain why EF-2 phosphorylation is mainly
restricted to that phase of the cell cycle. Moreover, other bands in
addition to EF-2 were phosphorylated in a calmodulin- and
PTA-dependent manner, and several of them (in a range
between 50 and 60 kDa) have similar Mr to those
that conform to the holoenzyme calcium/calmodulin dependent
protein kinase II, suggesting that PTA could have a more general
function modulating the activity of various
Ca2+/CaM-dependent enzymes along the cell
cycle.
 |
INTRODUCTION |
Prothymosin (PTA)1
is a small highly acidic protein (1, 2). PTA function may well be
related to normal cell proliferation, and the lines of evidence are as
follows: (a) PTA mRNA levels are induced in
serum-deprived fibroblasts 3T3 cells when they are stimulated to
proliferate (3, 4), and PTA mRNA expression is also correlated to
the proliferative activity of T cells and a small intestine-derived
cell line (5, 6); (b) immunohistochemical studies have also
shown that PTA is expressed in proliferating but not quiescent cells in
all tissues studied so far (7-12); (c) PTA mRNA
antisense oligomers were shown to inhibit cell division in myeloma
cells (13); (d) we and others have found that PTA levels are
increased in various human malignant tumors (7, 14-16).
PTA physiological function remains unknown. It is a nuclear protein
(17, 18) present throughout the cell cycle (4). PTA has been found
phosphorylated, although the physiological relevance of this finding is
not known (19, 20). On the other hand, the intracellular signaling
pathways governing PTA expression are poorly known. PTA expression
seems to be under the direct control of MYC (21-24); however, Mol
et al. (25) did not confirm this finding. Recently, Vareli
et al. (26) have reported that the transcription factor E2F
activates a reporter gene under the PTA promoter, indicating that E2F
could directly control PTA expression.
Calcium, an intracellular second messenger, is known to regulate
various cellular responses. Many aspects of calcium action are mediated
by calcium/calmodulin-dependent protein kinases
(CaM-kinases). There are different CaM-kinases controlling a wide range
of physiological processes including cell proliferation (27). In the
present report, we assessed phosphorylation changes in response to PTA presence in cell extracts and found that the phosphorylation state of
several proteins was affected. One of them was identified as the
eukaryotic elongation factor 2 (EF-2), suggesting that PTA activates
CaM-kinase III, thus providing a new link between calcium and other
mitogenic signaling pathways.
 |
EXPERIMENTAL PROCEDURES |
Materials--
PTA from bovine thymus was obtained from
Peninsula Laboratories Europe. Calmodulin from bovine brain and
calmodulin-agarose were from Sigma. Calmodulin inhibitors
trifluoperazine and W-7 were purchased from Calbiochem.
[ -32P]ATP was from Amersham Pharmacia Biotech.
Human Recombinant Prothymosin Expression and
Purification--
A polymerase chain reaction-modified human PTA
cDNA (28) was subcloned in the NdeI-EcoRI
sites of a T7-7 bacterial expression vector (29), and the recombinant
plasmid pEP was introduced into BL21(DE3)/pLysS cells (Novagen).
Bacterial cultures were grown to A600 ~ 1.0 and induced with 1 mM isopropyl
-D-thiogalactopyranoside for 1 h. Cells harvested
by centrifugation were resuspended in 5% perchloric acid, sonicated,
and cleared by centrifugation, and the supernatant (perchloric soluble
fraction) was stored at 80 °C. Perchloric soluble fraction was
neutralized with NaOH and precipitated with 2.5 volumes of ethanol at
20 °C overnight. Precipitated proteins were resuspended in
phosphate-buffered saline and subjected to phenol extraction (30) using
1 volume of phenol saturated in 0.3 M sodium acetate, pH
5.2, 150 mM NaCl at 65 °C. After vigorous mixing and
centrifugation, purified PTA was recovered in the aqueous phase,
desalted through a Sephadex G-50 minicolumn, and precipitated with
ethanol as above. Pellets were now resuspended in water and stored at
80 °C for no longer than 1 month. Protein purity and concentration
was determined by SDS-PAGE.
Cell Culture--
NIH 3T3 mouse fibroblasts were grown at
37 °C and 5% CO2 in a humid atmosphere, in Dulbecco's
modified Eagle's medium supplemented with 10% fetal calf serum, 2 mM glutamine. Cells were synchronized as described by
Zalvide et al. (4).
Human promyelocytic leukemia tumor cell line HL-60 was grown in RPMI
1640 medium with 2 mM glutamine, 10% fetal calf serum. Fisher rat thyroid cells, FRTL-5, were cultured in Coon's modified Ham's F-12 medium in the presence of a 5H hormone mixture as described previously (31).
Cell Extracts--
Cells were harvested by trypsinization
(monolayer cultures) or centrifugation (suspension cultures), washed
twice with ice-cold phosphate-buffered saline, resuspended in
homogenization buffer (50 mM Tris-HCl, pH 7.5, 0.1 mM EDTA, 1 mM dithiothreitol, 250 mM sucrose, 5 µg/ml soybean trypsin inhibitor, 2 µg/ml
leupeptin, 1 mM phenylmethylsulfonyl fluoride) and
sonicated. After centrifugation at 100,000 × g for 30 min, the supernatant was purified by gel filtration through Sephadex
G-50 and eluted in sucrose-free homogenization buffer. Protein
concentration in the supernatant was quantified with the Bio-Rad
dye-binding assay.
To deplete extracts of CaM-binding proteins, 2 mg of the cell extract
were made 2 mM Ca2+ by the addition of
CaCl2 and diluted 1:1 in washing buffer (40 mM
Tris-HCl, pH 7.5, 200 mM NaCl, 2 mM
CaCl2, 1 mM phenylmethylsulfonyl fluoride). The
diluted extract was then incubated with 400 µl of CaM-agarose beads
during 30 min at 4 °C. After incubation, the mixture was
centrifuged, and the supernatant was collected and stored.
Phosphorylation Assay--
Standard phosphorylation assays (50 µl) were performed with 5-20 µg of cell extract in 40 mM Hepes, pH 7.0, 3 mM MgCl2, 50 mM NaF, and 0.1 mM CaCl2 in the
presence or absence of the indicated amounts of PTA, EGTA, and CaM.
Phosphorylation was started by the addition of 10 µCi of
[ -32P]ATP (3000 Ci/mmol). Reactions were incubated at
37 °C for 5 min and then stopped by the addition of electrophoresis
sample buffer. Phosphorylated products were analyzed on 7.5% SDS-PAGE gels under reducing conditions. Gels were stained with Coomassie Blue,
dried, and subjected to autoradiography.
Protein Sequencing--
Samples for sequence analysis were
reduced with dithiothreitol and pyridylethylated with 4-vinylpyridine
in the sample buffer prior to running the gel electrophoresis. After
Coomassie staining, the 105-kDa band was excised from the gel and
subjected to "in gel" digestion with trypsin essentially as
described by Hellman et al. (32). Resulting internal tryptic
fragments were isolated by narrow bore reversed phase liquid
chromatography on a µRPC C2/C18 SC 2.1/10 column, operated in SMART
System (Amersham Pharmacia Biotech). Amino acid sequence analysis of
selected fragments was performed on an ABI model 470A gas phase
sequenator, following the manufacturer's instruction.
Western Blot Analysis--
Cell extracts phosphorylated in the
phosphorylation assay were subjected to SDS-PAGE and transferred onto
nitrocellulose filters. These were incubated overnight with a 1:2000
dilution of anti-EF-2 antiserum (33). Detection was performed with the
Western Light Immunoblotting System (Tropix).
 |
RESULTS |
When cell extracts obtained from exponentially growing NIH3T3
cells were incubated in the presence of radioactive ATP, several phosphorylated bands were observed. The addition of PTA to the reaction
affected this pattern, stimulating the phosphorylation of some of these
proteins. Initially, we focused on one of them, with an apparent
molecular mass of 105 kDa (p105), that was very weakly or not at all
phosphorylated in the absence of PTA (Fig. 1A), and its phosphorylation
was induced by PTA in a dose-dependent manner (Fig.
1B). Both bovine PTA and human recombinant PTA were active
in the phosphorylation assay (data not shown); thus, we used human PTA
to obtain the data reported in the present work. As seen in Fig.
1C, PTA also induced the phosphorylation of a 105-kDa
protein in extracts prepared from FRTL-5 and HL-60 cell lines, a normal
rat and a human tumor cell line, respectively, indicating that the
PTA-induced phopshorylation of the 105-kDa band might be a common
phenomenon in mammalian cell lines. When a large amount (20 µg) of
cell extract was used, the phosphorylation of p105 was observed even in
absence of exogenous PTA. Decreasing the ratio of cell extract to added
PTA produced a concomitant reduction of the phosphorylated p105 band,
pointing out that the stimulation of phosphorylation is dependent on
the amount of the extract added to the sample.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 1.
PTA induces the phosphorylation of a 105-kDa
protein. A, ten micrograms of extract from asynchronously
proliferating NIH3T3 cells were phosphorylated as described under
"Experimental Procedures" in the absence ( ) or presence (+) of 8 µM PTA and subjected to SDS-PAGE. The left
part (CBB) shows a dried Coomassie Blue-stained gel
where reactions were resolved, and the right part
(32P) shows the corresponding autoradiogram.
B, to show the dose-response effect of PTA on p105
phosphorylation, 20 µg of NIH3T3 cell extract were employed for
phosphorylation assays in the presence of the indicated amounts of PTA.
The reactions were resolved in SDS-PAGE and electrotransferred onto
nitrocellulose, and the filter was exposed to obtain the
autoradiography that is shown. C, the indicated amounts of
HL-60 cells extract (right part) or 20 µg of FRTL-5 cells
extract (left part) were subjected to phosphorylation assays
in the absence ( ) or presence (+) of 8 µM PTA to show
that PTA enhanced the phosphorylation of p105 in extracts from
different cell types. Samples were processed as described under
"Experimental Procedures," and an autoradiogram is shown. In each
panel, the positions of the molecular mass markers are
indicated. The arrows mark the position of p105.
|
|
To gain an insight into the conditions needed for the phosphorylation
of p105, we explored its Ca2+ requirements. The addition of
EGTA abolished the PTA-induced p105 phosphorylation, while the addition
of Ca2+, at concentrations as low as 0.1 µM,
restored that effect, showing that the presence of Ca2+ is
required for the phosphorylation effect (Fig.
2).

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 2.
PTA-dependent phosphorylation of
p105 requires the presence of Ca2+. Autoradiogram of
SDS-PAGE of phosphorylation assays carried out with 10 µg of NIH3T3
cells extract without exogenous Ca2+ (two leftmost
lanes) and in the presence of the indicated amounts of EGTA
(third lane) and in the presence of EGTA and exogenous
Ca2+ to achieve the concentration of Ca2+
indicated (four rightmost lanes). PTA at a concentration of
8 µM was added in the samples loaded in the lanes marked
with a plus sign. The p105 band is indicated by the
arrow.
|
|
The p105 band was isolated from HL-60 extracts, and its internal
peptide fragments were obtained by the in gel digestion procedure. Two
fragments were characterized with the following sequences: FSVSPVV and
FDVHDVTLHADAI. These sequences corresponded with the fragments 499-505
and 702-714 of EF-2. Further immunological analysis by Western blot,
using a polyclonal antibody against EF-2 (a generous gift from Dr.
Angus C. Nairn), showed that indeed p105 and EF-2 comigrate in SDS-PAGE
(Fig. 3). Moreover, we found that PTA
modified the phosphorylation of EF-2 without affecting the amount of
this protein present in the cell extract.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 3.
Immunological identity of p105 and EF-2.
Proteins from standard phosphorylation reactions were run in SDS-PAGE
and electrotransferred onto a nitrocellulose filter. The membrane was
exposed to obtain an autoradiogram (upper panel). After the
decay of the radioactive signal, the same filter was subjected to a
Western blot (WB) with an antiserum against EF-2. The
chemiluminiscent register is shown in the lower panel.
|
|
To our knowledge, CaM-kinase III is the only known kinase that
phosphorylates EF-2, and EF-2 is the only known substrate for CaM-kinase III, at least in vitro (34). So we studied
whether the PTA-induced phosphorylation of EF-2 might be mediated by
CaM-kinase III. To do this, we exploited the fact that CaM-kinase III
binds CaM with high affinity and depleted the cell extracts of
CaM-binding proteins by means of CaM affinity chromatography. As Fig.
4 shows, EF-2 phosphorylation was not
detectable in the presence of PTA when the extracts were depleted from
CaM-binding proteins despite the fact that EF-2 was still present
(albeit at half the amount present in total extracts (data not shown)),
strongly suggesting that CaM-kinase III, a CaM-binding protein,
mediates the effect of PTA.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 4.
The PTA effect on EF-2 phosphorylation is
mediated by CaM-binding proteins. The same amount (10 µg) of
standard extracts (WE) or extracts depleted of CaM-binding
proteins by means of CaM affinity chromatography (DE) was
subjected to phosphorylation reactions in presence of PTA (8 µM). Proteins were resolved by SDS-PAGE and detected by
autoradiography. The arrow indicates the position of the
EF-2 phosphorylated band.
|
|
Since calmodulin is the main activator of CaM-kinases, we tested
the effect of the simultaneous addition of PTA and CaM to cell
extracts. Fig. 5A shows that
the simultaneous addition of PTA and CaM caused a reinforcement of
phosphorylated EF-2 band in a synergistic way. Other bands in a range
between 50 and 60 kDa were phosphorylated in a CaM- and
PTA-dependent manner (Fig. 5A, open
arrow). Next, to determine if PTA-stimulated phosphorylation of
EF-2 depended on CaM activity, two widely used CaM inhibitors were
employed in the reactions. W-7 inhibited the stimulation due to PTA
alone or to the addition of PTA plus CaM (Fig. 5B), and
trifluoperazine inhibited the PTA effect in a
dose-dependent manner (Fig. 5C).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 5.
Influence of CaM activity on PTA-induced
phosphorylation of EF-2. A, phosphorylation assays were
carried out with 20 µg of NIH3T3 cell extract in the presence of the
indicated amounts of PTA and CaM (Sigma). After resolving the reactions
by SDS-PAGE, the corresponding autoradiogram was obtained, and it is
shown in the figure. The solid arrow marks the
position of the EF-2 band; the open arrow indicates the
migration of several other bands phosphorylated in a PTA- and
CaM-dependent manner (see "Results"). B,
reactions were done with 20 µg of cell extract in the presence of 8 µM of PTA or CaM, as indicated (+). CaM inhibitor W-7,
when added, was employed at 10 µM. The arrow
marks the position of EF-2. C, CaM inhibitor trifluoperazine
was added at the indicated concentrations to standard phosphorylation
reactions containing PTA but not CaM. The data from densitometry of
autoradiograms from three independent experiments are shown as
mean ± S.E.
|
|
We further investigated the PTA-induced phosphorylation of EF-2 in
different stages of the cell cycle. Such phosphorylation was not
detectable when reactions were performed with extracts from
serum-starved quiescent NIH3T3 cells even in the presence of exogenous
PTA, pointing out that some essential factor is not present, at least
in sufficient amounts, in quiescent cells; this essential factor is not
EF-2 that was present in the quiescent extracts as seen by Western blot
(data not shown). Eight hours after serum refeeding, PTA induced the
phosphorylation of EF-2 (Fig.
6A). PTA-dependent
phosphorylation of EF-2 was detectable in extracts from cells
synchronized at different points between S and M phases of the cell
cycle. The basal phosphorylation of EF-2, without exogenous PTA, was
also seen albeit at a lower amount than when PTA was added (Fig.
6B). Interestingly, in nocodazole-arrested cells, the
addition of PTA was not necessary to see a strong band of
phosphorylated EF-2 (Fig. 6B). In all samples, the band of phosphorylated EF-2 reached similar intensity in the presence of PTA,
independently of the basal phosphorylation observed, suggesting that
the stimulated pathway is the same in both cases (with or without
exogenous PTA). Since PTA is a nuclear protein everywhere in the cell
cycle except in mitosis, when it is found in the cytoplasm (data not
shown), nocodazole-arrested cells (mitotic cells) represent a situation
when PTA-induced EF-2 phosphorylation might have a physiological
significance, since PTA, CaM-kinase III, and EF-2 are found together in
the cytoplasm.

View larger version (62K):
[in this window]
[in a new window]
|
Fig. 6.
PTA-induced phosphorylation of EF-2 along
cell cycle. A, NIH3T3 cells were synchronized by serum
starvation as described. Extracts were obtained from nonproliferating
quiescent cells (0) or from serum-refed cells for 8 h
(8) and subjected to phosphorylation assays in the absence
( ) or presence (+) of PTA (8 µM). B,
phosphoprotein pattern in extracts obtained from cells synchronized in
different stages of the cell cycle: cells arrested by double thymidine
block (T0) and 3 (T3), 6 (T6), and
9 h (T9) after block release and mitotic cells obtained
by nocodazole arrest (N). The arrows mark the
position of EF-2.
|
|
 |
DISCUSSION |
Here we report that in cell extracts PTA stimulates the
phosphorylation of several proteins. Initially, we focused on one of
them, with an apparent molecular mass of 105 kDa, that was very weakly
or not at all phosphorylated in the absence of PTA, and its
phosphorylation was induced by PTA in a dose-dependent manner. Two fragments of this band were characterized with sequences that were identical to the eukaryotic elongation factor 2, an essential
factor for the extension of the polypeptide chain in the ribosome.
Further immunological analysis by Western blot, using a polyclonal
antibody against EF-2, confirmed this identity, showing that indeed
p105 and EF-2 comigrated in SDS-PAGE. Moreover, we found that PTA
modified the EF-2 phosphorylation without affecting the amount of EF-2
present in the cell extract. To our knowledge, CaM-kinase III is the
only known kinase that phosphorylates EF-2 (34). We think that
CaM-kinase III is responsible for the PTA-stimulated EF-2
phosphorylation based on the following evidence: (a)
Ca2+ is required; (b) calmodulin enhances the
reaction, and calmodulin inhibitors block the phosphorylation;
(c) no phosphorylation is seen in extracts depleted of
CaM-binding proteins. Moreover, we found PTA-induced phosphorylation of
EF-2 in various cell lines in agreement with the finding that
CaM-kinase III has a widespread tissue distribution (33). On the other
hand, quiescent, nonproliferating cells did not show kinase activity
despite the addition of PTA to the reaction, indicating that some other
factor was lacking in the extracts from nonproliferating cells. This
finding could be explained by the fact that CaM-kinase III is present
at low levels in nondividing cells (35, 36).
The mechanism by which PTA stimulates EF-2 phosphorylation is not
clear now. Several scenarios can be proposed: (a) PTA may directly act on CaM-kinase III; (a) PTA may displace CaM
from binding sites on proteins present in the cell extracts, increasing its availability to bind CaM-kinase III; or (c) PTA may bind
to EF-2 and conformationally alter the latter, resulting in exposure of
new sites of phosphorylation. These alternate scenarios may be
distinguished by future experiments.
When eukaryotic cells undergo mitosis, the rate of protein synthesis
declines by up to 35-40%. This decline is due to phosphorylation of
EF-2 (37), since this phosphorylation affects the rate of translation
(38, 39). To obtain a strong phosphorylated EF-2 band, we found it
necessary to add exogenous PTA to cytosolic extracts prepared from
synchronized dividing cells in the various phases of the cell cycle
except in mitosis. In mitotic cell extracts, the addition of exogenous
PTA did not further enhance EF-2 phosphorylation, as if the reaction
was already saturated with endogenous PTA. Interestingly, PTA is a
nuclear protein throughout the cell cycle except in mitosis, when it is
found in the cytoplasm; therefore, if PTA modulates EF-2
phosphorylation, as present data suggest, then it could be explained
why EF-2 phosphorylation is mainly restricted to mitosis despite the
presence of both CaM-kinase III and EF-2 in the cytoplasm throughout
the cell cycle.
Moreover, other bands in addition to EF-2 were phosphorylated in a CaM-
and PTA-dependent manner (Fig. 5A); the apparent
molecular masses of these bands (in a range between 50 and 60 kDa) are
similar to those reported for the different subunits that conform the holoenzyme CaM-kinase II. Initial evidence obtained by Western blot
using an anti-CaM-kinase II antibody points to the fact that these bands are in fact CaM-kinase
II,2 suggesting that PTA
could have a more general function modulating the activity of various
Ca2+/CaM-dependent enzymes throughout the cell
cycle.
MYC has been reported to induce PTA expression (21-24). More recently,
E2F has also been implicated in promoting PTA expression (26). Here we
present evidence that PTA modulates the activity of CaM-kinases.
Therefore, if the present findings are confirmed in vivo,
PTA could represent a novel link between various intracellular signaling mitogenic pathways such as Ca2+, MYC, and E2F.
Studies to assess this issue are currently under way.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Angus C. Nairn (Rockefeller
University, New York) for providing anti-EF-2 antiserum. We
also thank Puri Vázquez for technical support and Dr. Juan B. Zalvide for critical reading of this manuscript.
 |
FOOTNOTES |
*
This work was supported in part by grants from Fondo de
Investigaciones Sanitarias de la Seguridad Social and
Consellería de Sanidade e Servicios Sociais, Dirección
Xeral de Saúde Pública, Programa de Screening de Cancer de
Mama (to F. D.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
These two authors equally contributed to this work.
To whom correspondence should be addressed: Dept. de
Fisiología, Facultad de Medicina, Universidad de Santiago,
15705 Santiago, Spain. Tel.: 34 81 582658; Fax: 34 81 574145; E-mail:
fsfedopu{at}usc.es.
1
The abbreviations used are: PTA, prothymosin
; CaM-kinase, calcium/calmodulin-dependent protein kinase;
CaM, calmodulin; PAGE, polyacrylamide gel electrophoresis; EF-2,
eukaryotic elongation factor 2; W-7, N(6-
aminohexyl)-5-chloro-1-naphtalene-sulfonamide.
2
A. Vidal, G. Barisone, F. V. Vega, V. Hellman,
C. Wernstedt, and F. Domínquez, unpublished observations.
 |
REFERENCES |
-
Haritos, A. A.,
Goodall, G. J.,
and Horecker, B. L.
(1984)
Proc. Natl. Acad. Sci. U. S. A.
81,
1008-1011[Abstract/Free Full Text]
-
Haritos, A. A.,
Blacher, R.,
Stein, S.,
Caldarella, J.,
and Horecker, B. L.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
343-346[Abstract/Free Full Text]
-
Eschenfeldt, W. H.,
and Berger, S. L.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
83,
9403-9407[Abstract/Free Full Text]
-
Zalvide, J. B.,
Cancio, E.,
Alvarez, C. V.,
Regueiro, B. J.,
and Domínguez, F.
(1992)
J. Biol. Chem.
267,
8692-8695[Abstract/Free Full Text]
-
Conteas, C. N.,
Mutchink, M. G.,
Palmer, K. C.,
Weller, F. E.,
Luk, G. D.,
Naylor, P. H.,
Erdos, M. R.,
Goldstein, A. L.,
Panneerselvam, C.,
and Horecker, B. L.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
3269-3273[Abstract/Free Full Text]
-
Gómez-Márquez, J.,
Segade, F.,
Dosil, M.,
Pichel, J. G.,
Bustelo, X. R.,
and Freire, M.
(1989)
J. Biol. Chem.
264,
8451-8454[Abstract/Free Full Text]
-
Fraga, M.,
García-Caballero, T.,
Domínguez, F.,
Pérez-Becerra, E.,
Beiras, A.,
and Forteza, J.
(1993)
Virchows Arch. A Pathol. Anat. Histopathol.
423,
449-452[CrossRef][Medline]
[Order article via Infotrieve]
-
Gallego, R.,
Rosón, E.,
García-Caballero, T.,
Fraga, M.,
Forteza, J.,
Domínguez, F.,
and Beiras, A.
(1992)
Acta Anat.
143,
219-222[Medline]
[Order article via Infotrieve]
-
García-Caballero, T.,
Domínguez, F.,
Rosón, E.,
Gallego, R.,
Zalvide, J.,
Forteza, J.,
and Beiras, A.
(1994)
Anat. Rec.
239,
88-94[CrossRef][Medline]
[Order article via Infotrieve]
-
Rosón, E.,
Gallego, R.,
García-Caballero, T.,
Fraga, M.,
Domínguez, F.,
and Beiras, A.
(1993)
Histochem. J.
25,
497-501[CrossRef][Medline]
[Order article via Infotrieve]
-
Rosón, E.,
Gallego, R.,
García -Caballero, T.,
Heimer, E. P.,
Felix, A. M.,
and Domínguez, F.
(1990)
Histochemistry
94,
597-599[Medline]
[Order article via Infotrieve]
-
Rosón, E.,
García-Caballero, T.,
Heimer, E. P.,
Felix, A. M.,
and Domínguez, F.
(1990)
J. Histochem. Cytochem.
38,
1889-1894[Abstract]
-
Sburlati, A. R.,
Manrow, R. E.,
and Berger, S. L.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
253-257[Abstract/Free Full Text]
-
Tsitsiloni, O. E.,
Stiakakis, J.,
Koutselinis, A.,
Gogas, J.,
Markopoulos, C.,
Yialouris, P.,
Bekris, S.,
Panoussopoulos, D.,
Kiortsis, V,
Voelter, W.,
and Haritos, A. A.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
9504-9507[Abstract/Free Full Text]
-
Domínguez, F.,
Magdalena, C.,
Cancio, E.,
Paredes, J.,
Loidi, L.,
Zalvide, J.,
Fraga, M.,
Forteza, J.,
Regueiro, B. J.,
and Puente, J. L.
(1993)
Eur. J. Cancer
29A,
893-897[CrossRef]
-
Mori, M.,
Barnard, G. F.,
Staniunas, R. J.,
Jessup, J. M.,
Steele, G. D., Jr.,
and Chen, L. B.
(1993)
Oncogene
8,
2821-2826[Medline]
[Order article via Infotrieve]
-
Gómez-Márquez, J.,
and Segade, F.
(1988)
FEBS Lett.
226,
217-219[CrossRef][Medline]
[Order article via Infotrieve]
-
Manrow, R. E.,
Sburlati, A. R.,
Hanover, J. A.,
and Berger, S. L.
(1991)
J. Biol. Chem.
266,
3916-3924[Abstract/Free Full Text]
-
Barcia, M. G.,
Castro, J. M.,
Jullien, C. D.,
and Freire, M.
(1993)
J. Biol. Chem.
268,
4704-4708[Abstract/Free Full Text]
-
Sburlati, A. R.,
DeLarosa, A.,
Batey, D. W.,
Kurys, G. L.,
Manrow, R. E.,
Pannell, L. K.,
Martin, B. M.,
Sheeley, D. M.,
and Berger, S. L.
(1993)
Biochemistry
32,
4587-4596[CrossRef][Medline]
[Order article via Infotrieve]
-
Eilers, M.,
Schirm, S.,
and Bishop, J. M.
(1991)
EMBO J.
10,
133-141[Medline]
[Order article via Infotrieve]
-
Gaubatz, S,
Meichle, A.,
and Eilers, M.
(1994)
Mol. Cell. Biol.
14,
3853-3862[Abstract/Free Full Text]
-
Desbarats, L.,
Gaubatz, S.,
and Eilers, M.
(1996)
Genes Dev.
10,
447-460[Abstract/Free Full Text]
-
Lutz, W,
Stöhr, M.,
Schürmann, J.,
Wenzel, A.,
Löhr, A.,
and Schwab, M.
(1996)
Oncogene
13,
803-812[Medline]
[Order article via Infotrieve]
-
Mol, P. C.,
Wang, R-H.,
Batey, D. W.,
Lee, L. A.,
Dang, C. V.,
and Berger, S. L.
(1995)
Mol. Cell. Biol.
15,
6999-7009[Abstract]
-
Vareli, K.,
Tsolas, O.,
and Frangou-Lazaridis, M.
(1996)
Eur. J. Biochem.
238,
799-806[Medline]
[Order article via Infotrieve]
-
Means, A. R.
(1994)
FEBS Lett.
347,
1-4[CrossRef][Medline]
[Order article via Infotrieve]
-
Goodall, G. J.,
Domínguez, F.,
and Horecker, B. L.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
83,
8926-8928[Abstract/Free Full Text]
-
Tabor, S.,
and Richardson, C. C.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
1074-1078[Abstract/Free Full Text]
-
Sburlati, A. R.,
Manrow, R. E.,
and Berger, S. L.
(1990)
Protein Expression Purif.
1,
184-190[CrossRef][Medline]
[Order article via Infotrieve]
-
Alvarez, C. V.,
Zalvide, J. B.,
Cancio, E.,
Diéguez, C.,
Regueiro, B. J.,
Vega, F. V.,
and Domínguez, F.
(1993)
J. Mol. Endocrinol.
11,
249-256[Abstract/Free Full Text]
-
Hellman, U.,
Wernstedt, C.,
Goñez, J.,
and Heldin, C. H.
(1995)
Anal. Biochem.
224,
451-455[CrossRef][Medline]
[Order article via Infotrieve]
-
Nairn, A. C.,
Bhaget, B.,
and Palfrey, H. C.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
7939-7943[Abstract/Free Full Text]
-
Nairn, A. C.,
and Picciotto, M. R.
(1994)
Semin. Cancer Biol.
5,
295-303[Medline]
[Order article via Infotrieve]
-
Brady, M. J.,
Nairn, A. C.,
Wagner, J. A.,
and Palfrey, H. C.
(1990)
J. Neurochem.
54,
1034-1039[Medline]
[Order article via Infotrieve]
-
Bagaglio, D. M.,
Cheng, E. H. C.,
Gorelick, F. S.,
Mitsui, K.,
Nairn, A. C.,
and Hait, W. N.
(1993)
Cancer Res.
53,
2260-2264[Abstract/Free Full Text]
-
Celis, J. E.,
Madsen, P.,
and Ryazanov, A. G.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
4231-4235[Abstract/Free Full Text]
-
Nairn, A. C.,
and Palfrey, H. C.
(1987)
J. Biol. Chem.
262,
17299-17303[Abstract/Free Full Text]
-
Ryazanov, A. G.,
Shestakova, E. A.,
and Natapov, P. G.
(1988)
Nature
334,
170-173[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. G. Blanco, F. Boan, and J. Gomez-Marquez
A Paradox in the in Vitro End-joining Assays
J. Biol. Chem.,
June 18, 2004;
279(25):
26797 - 26801.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Enkemann, R. D. Ward, and S. L. Berger
Mobility Within the Nucleus and Neighboring Cytosol Is a Key Feature of Prothymosin-{alpha}
J. Histochem. Cytochem.,
October 1, 2000;
48(10):
1341 - 1356.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
S. A. Enkemann, K. S. Pavur, A. G. Ryazanov, and S. L. Berger
Does Prothymosin alpha Affect the Phosphorylation of Elongation Factor 2?
J. Biol. Chem.,
June 25, 1999;
274(26):
18644 - 18650.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Trompeter, A Schiermeyer, G Blankenburg, E Hennig, and H. Soling
Factors involved in the cell density-dependent regulation of nuclear/cytoplasmic distribution of the 11.5-kDa Zn(2+)-binding protein (parathymosin-alpha) in rat hepatocytes
J. Cell Sci.,
January 11, 1999;
112(22):
4113 - 4122.
[Abstract]
[PDF]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|